Intoplicine - Sanofi Oncology

Drug Profile

Intoplicine - Sanofi Oncology

Alternative Names: NSC-645008; RP 60475

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ILEX Oncology Inc
  • Class Indoles; Pyridines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cancer metastases; Solid tumours

Most Recent Events

  • 27 Aug 2018 Genzyme completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada (IV-infusion) (NCT00003713)
  • 17 Jun 2002 Discontinued - Phase-I for Cancer metastases in USA (IV-infusion)
  • 17 Jun 2002 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top